Back to News
Market Impact: 0.25
Saluda Medical Expands Surgical Access To Evoke Therapy With CAP24
Source: Nasdaq
Healthcare & BiotechProduct Launches
Saluda Medical completed the full U.S. commercial release of its CAP24 Surgical Paddle Lead after receiving FDA approval earlier this year. The article provides no sales figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Meta may ditch the idea of a cloud business for Muse. We think that’s a good trade
- Why is Telix Pharmaceuticals stock rallying today?
- Mistral unveils new AI model it says rivals best open systems from China
- Muse has been a boon for Meta. It can soar much higher, Wells Fargo says
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace
- AI Research Tools for SEDAR+, UK and ASX Filings